Symbols / OMER Stock $13.53 +0.07% Omeros Corporation

Healthcare • Biotechnology • United States • NGM
OMER (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Gregory A. Demopulos M.D.
Exch · Country NGM · United States
Market Cap 974.11M
Enterprise Value 1.05B
Income -4.81M
Sales —
FCF (ttm) 170.34M
Book/sh -1.69
Cash/sh 2.39
Employees 175
Insider 10d —
IPO Oct 08, 2009
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 10.52
PEG 0.81
P/S —
P/B -8.00
P/C —
EV/EBITDA -8.64
EV/Sales —
Quick Ratio 2.34
Current Ratio 2.76
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.08
EPS next Y 1.29
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-31
ROA -25.47%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 72.00M
Shs Float 69.28M
Insider Own 2.80%
Instit Own 46.78%
Short Float 24.34%
Short Ratio 14.37
Short Interest 16.90M
52W High 17.65
vs 52W High -23.34%
52W Low 2.95
vs 52W Low 358.64%
Beta 2.53
Impl. Vol. 3.13%
Rel Volume 1.45
Avg Volume 1.05M
Volume 1.52M
Target (mean) $38.00
Tgt Median $38.00
Tgt Low $36.00
Tgt High $40.00
# Analysts 2
Recom Buy
Prev Close $13.52
Price $13.53
Change 0.07%
About

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.00
Mean price target
2. Current target
$13.53
Latest analyst target
3. DCF / Fair value
$42.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.53
Low
$36.00
High
$40.00
Mean
$38.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 main D. Boral Capital Buy → Buy $36
2026-01-27 main D. Boral Capital Buy → Buy $36
2026-01-08 main HC Wainwright & Co. Buy → Buy $40
2026-01-08 main D. Boral Capital Buy → Buy $36
2025-12-24 main D. Boral Capital Buy → Buy $36
2025-12-01 main D. Boral Capital Buy → Buy $36
2025-11-14 main D. Boral Capital Buy → Buy $36
2025-10-16 main D. Boral Capital Buy → Buy $36
2025-10-15 reit Needham Hold → Hold —
2025-10-15 reit WBB Securities Strong Buy → Strong Buy $45
2025-10-15 main HC Wainwright & Co. Buy → Buy $20
2025-10-15 main D. Boral Capital Buy → Buy $36
2025-09-03 main D. Boral Capital Buy → Buy $36
2025-08-15 main D. Boral Capital Buy → Buy $36
2025-08-15 reit Needham Hold → Hold —
2025-07-25 main D. Boral Capital Buy → Buy $36
2025-06-30 main D. Boral Capital Buy → Buy $36
2025-06-10 init HC Wainwright & Co. — → Buy $9
2025-05-16 reit Needham Hold → Hold —
2025-05-13 main D. Boral Capital Buy → Buy $36
News
RSS: Latest OMER news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 DEMOPULOS GREGORY A. M.D. Chief Executive Officer — 400,000 $10.27 $4,108,000
2026-01-13 BORGES DAVID J. Officer — 60,000 $12.31 $750,915
2026-01-13 BORGES DAVID J. Officer — 30,000 $3.06 $91,800
2025-10-13 DEMOPULOS GREGORY A. M.D. Chief Executive Officer — 600,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
—
Reconciled Cost Of Revenue
—
—
—
—
Gross Profit
—
—
—
—
Operating Expense
122.80
-26.45%
166.95
+1.47%
164.53
+0.70%
163.39
Research And Development
81.30
-31.98%
119.52
+4.05%
114.87
+1.91%
112.72
Selling General And Administration
41.50
-12.50%
47.43
-4.49%
49.66
-1.99%
50.67
General And Administrative Expense
41.50
-12.50%
47.43
-4.49%
49.66
-1.99%
50.67
Salaries And Wages
4.66
-26.70%
6.36
-10.92%
7.14
-11.22%
8.04
Other Gand A
36.84
-10.30%
41.07
-3.41%
42.52
-0.25%
42.63
Total Expenses
122.80
-26.45%
166.95
+1.47%
164.53
+0.70%
163.39
Operating Income
-122.80
+26.45%
-166.95
-1.47%
-164.53
-0.70%
-163.39
Total Operating Income As Reported
-122.80
+26.45%
-166.95
-1.47%
-164.53
-0.70%
-163.39
EBITDA
-121.83
+21.25%
-154.70
-8.06%
-143.16
+9.61%
-158.38
Normalized EBITDA
-236.78
-53.04%
-154.72
-5.06%
-147.27
+7.01%
-158.38
Reconciled Depreciation
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
EBIT
-122.80
+21.11%
-155.65
-8.03%
-144.08
+9.57%
-159.33
Total Unusual Items
114.94
+604868.42%
0.02
-99.54%
4.11
0.00
Total Unusual Items Excluding Goodwill
114.94
+604868.42%
0.02
-99.54%
4.11
0.00
Special Income Charges
251.66
0.00
-100.00%
4.11
0.00
Other Special Charges
-14.07
—
-4.11
—
Net Income
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Pretax Income
-2.80
+98.45%
-180.32
-3.09%
-174.92
+3.91%
-182.03
Net Non Operating Interest Income Expense
5.06
+137.76%
-13.39
+7.67%
-14.50
+22.20%
-18.64
Interest Expense Non Operating
—
24.68
-20.00%
30.84
+35.86%
22.70
Net Interest Income
5.06
+137.76%
-13.39
+7.67%
-14.50
+22.20%
-18.64
Interest Expense
—
24.68
-20.00%
30.84
+35.86%
22.70
Interest Income Non Operating
5.06
-55.20%
11.29
-30.94%
16.34
+302.31%
4.06
Interest Income
5.06
-55.20%
11.29
-30.94%
16.34
+302.31%
4.06
Other Income Expense
114.94
+604868.42%
0.02
-99.54%
4.11
—
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
-136.72
-719663.16%
0.02
—
—
Gain On Sale Of Business
237.59
—
—
—
Tax Provision
2.01
-12.71%
2.31
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
24.14
+604868.42%
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Net Income From Continuing Operation Net Minority Interest
-4.81
+97.37%
-182.63
-4.41%
-174.92
+3.91%
-182.03
Net Income From Continuing And Discontinued Operation
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Net Income Continuous Operations
-4.81
+97.37%
-182.63
-4.41%
-174.92
+3.91%
-182.03
Net Income Discontinuous Operations
1.46
-94.35%
25.81
-54.80%
57.11
-75.11%
229.45
Normalized Income
-95.61
+47.65%
-182.64
-2.02%
-179.03
+1.65%
-182.03
Net Income Common Stockholders
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Diluted EPS
-0.05
+98.15%
-2.70
-43.62%
-1.88
-347.37%
0.76
Basic EPS
-0.05
+98.15%
-2.70
-43.62%
-1.88
-347.37%
0.76
Basic Average Shares
63.51
+9.18%
58.17
-7.28%
62.74
+0.00%
62.74
Diluted Average Shares
63.51
+9.18%
58.17
-7.28%
62.74
+0.00%
62.74
Diluted NI Availto Com Stockholders
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
325.63
+17.52%
277.08
-26.75%
378.27
-35.99%
590.97
Current Assets
215.67
+60.80%
134.12
-38.45%
217.90
-50.84%
443.24
Cash Cash Equivalents And Short Term Investments
171.80
+90.61%
90.13
-47.55%
171.85
-11.84%
194.92
Cash And Cash Equivalents
9.66
+184.12%
3.40
-52.15%
7.11
-35.46%
11.01
Other Short Term Investments
162.14
+86.95%
86.73
-47.35%
164.74
-10.42%
183.91
Receivables
36.27
-1.50%
36.82
-1.73%
37.47
-84.52%
242.02
Accounts Receivable
6.44
-7.16%
6.94
+3.21%
6.72
-96.84%
212.97
Other Receivables
29.82
-0.19%
29.88
-2.81%
30.75
+5.83%
29.05
Prepaid Assets
—
—
—
—
Other Current Assets
7.59
+5.99%
7.17
-16.49%
8.58
+36.21%
6.30
Total Non Current Assets
109.97
-23.08%
142.96
-10.86%
160.37
+8.55%
147.73
Net PPE
12.48
-29.27%
17.64
-14.29%
20.58
-11.49%
23.25
Gross PPE
24.51
-14.63%
28.71
-6.85%
30.82
-6.04%
32.80
Accumulated Depreciation
-12.04
-8.71%
-11.07
-8.11%
-10.24
-7.26%
-9.55
Properties
—
0.00
0.00
0.00
Buildings And Improvements
—
14.96
-19.70%
18.63
-14.39%
21.76
Machinery Furniture Equipment
1.74
+0.00%
1.74
+0.00%
1.74
+2.12%
1.70
Other Properties
22.77
-15.57%
26.97
-7.26%
29.09
-6.48%
31.10
Non Current Accounts Receivable
96.44
-22.40%
124.27
-10.43%
138.74
+12.41%
123.42
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
1.05
+0.00%
1.05
+0.00%
1.05
+0.00%
1.05
Total Liabilities Net Minority Interest
446.86
-2.79%
459.69
+14.00%
403.25
-20.19%
505.29
Current Liabilities
78.06
-1.84%
79.53
+49.16%
53.32
-60.91%
136.38
Payables And Accrued Expenses
21.33
-6.68%
22.86
-29.01%
32.20
+7.78%
29.88
Payables
5.91
-0.84%
5.96
-22.72%
7.71
+28.77%
5.99
Accounts Payable
4.76
-19.32%
5.91
-23.43%
7.71
+28.77%
5.99
Current Accrued Expenses
15.42
-8.75%
16.90
-30.99%
24.49
+2.52%
23.89
Pensionand Other Post Retirement Benefit Plans Current
10.35
+16.69%
8.87
+20.16%
7.38
+10.73%
6.67
Total Tax Payable
1.15
+1983.64%
0.06
—
4.87
Income Tax Payable
1.15
+1983.64%
0.06
—
4.87
Current Debt And Capital Lease Obligation
23.36
-13.38%
26.97
+422.69%
5.16
-94.77%
98.69
Current Debt
17.06
-18.75%
21.00
—
94.38
Other Current Borrowings
17.06
-18.75%
21.00
—
94.38
Current Capital Lease Obligation
6.30
+5.51%
5.97
+15.72%
5.16
+19.72%
4.31
Current Deferred Liabilities
2.47
+1251.37%
0.18
—
—
Current Deferred Revenue
2.47
+1251.37%
0.18
—
—
Other Current Liabilities
20.55
-0.47%
20.64
+140.73%
8.58
+644.44%
1.15
Total Non Current Liabilities Net Minority Interest
368.80
-2.99%
380.16
+8.64%
349.94
-5.14%
368.90
Long Term Debt And Capital Lease Obligation
215.78
+19.85%
180.05
-22.16%
231.30
-4.95%
243.33
Long Term Debt
208.53
+25.18%
166.58
-21.85%
213.16
-3.51%
220.91
Long Term Capital Lease Obligation
7.25
-46.20%
13.47
-25.78%
18.14
-19.10%
22.43
Other Non Current Liabilities
147.32
-24.69%
195.61
+67.84%
116.55
-6.85%
125.13
Stockholders Equity
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Common Stock Equity
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Capital Stock
0.72
+23.45%
0.58
-5.07%
0.61
-2.71%
0.63
Common Stock
0.72
+23.45%
0.58
-5.07%
0.61
-2.71%
0.63
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
71.67
+23.48%
58.04
-5.05%
61.13
-2.71%
62.83
Ordinary Shares Number
71.67
+23.48%
58.04
-5.05%
61.13
-2.71%
62.83
Additional Paid In Capital
791.75
+8.88%
727.16
-0.11%
727.94
+0.99%
720.77
Retained Earnings
-913.70
-0.37%
-910.35
-20.81%
-753.53
-18.53%
-635.72
Total Equity Gross Minority Interest
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Total Capitalization
87.30
+644.76%
-16.03
-108.52%
188.17
-38.62%
306.59
Working Capital
137.60
+152.05%
54.59
-66.83%
164.58
-46.36%
306.85
Invested Capital
104.37
+1998.25%
4.97
-97.36%
188.17
-53.07%
400.97
Total Debt
239.14
+15.52%
207.02
-12.45%
236.46
-30.86%
342.02
Net Debt
215.94
+17.24%
184.18
-10.61%
206.05
-32.28%
304.28
Capital Lease Obligations
13.54
-30.31%
19.44
-16.59%
23.30
-12.84%
26.74
Net Tangible Assets
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Tangible Book Value
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Interest Payable
0.62
-76.90%
2.67
-37.13%
4.24
-17.98%
5.17
Non Current Accrued Expenses
5.70
+26.68%
4.50
+115.57%
2.09
+370.27%
0.44
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-116.09
+21.98%
-148.80
-299.13%
74.73
+186.41%
-86.48
Cash Flow From Continuing Operating Activities
-116.09
+21.98%
-148.80
-299.13%
74.73
+186.41%
-86.48
Net Income From Continuing Operations
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Depreciation Amortization Depletion
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
Depreciation And Amortization
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
Other Non Cash Items
-37.13
-8.16%
-34.33
+37.16%
-54.63
-84.77%
-29.57
Stock Based Compensation
8.19
-21.93%
10.49
-9.93%
11.65
-17.21%
14.07
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
-255.21
—
-4.11
—
Unrealized Gain Loss On Investment Securities
136.72
+719663.16%
-0.02
0.00
—
Change In Working Capital
33.72
-4.45%
35.29
-85.74%
247.42
+307.30%
-119.36
Change In Receivables
30.45
-23.90%
40.01
-83.72%
245.72
+324.14%
-109.63
Changes In Account Receivables
-3.18
-990.20%
0.36
-99.83%
205.12
+217.17%
-175.07
Change In Prepaid Assets
-1.31
-353.58%
0.52
+117.36%
-2.98
-418.84%
0.93
Change In Payables And Accrued Expense
4.58
+187.46%
-5.24
-211.90%
4.68
+143.90%
-10.66
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
—
—
—
—
Investing Cash Flow
164.52
+100.11%
82.22
+199.47%
27.45
+121.52%
-127.56
Cash Flow From Continuing Investing Activities
164.52
+100.11%
82.22
+199.47%
27.45
+121.52%
-127.56
Net PPE Purchase And Sale
239.94
+145515.15%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Purchase Of PPE
-0.07
+60.61%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Sale Of PPE
240.00
0.00
0.00
—
Capital Expenditure
-0.07
+60.61%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Net Investment Purchase And Sale
-75.41
-191.54%
82.38
+195.49%
27.88
+121.88%
-127.45
Purchase Of Investment
-185.31
+81.23%
-987.38
+3.06%
-1,018.60
-137.41%
-429.05
Sale Of Investment
109.90
-89.73%
1,069.77
+2.23%
1,046.48
+246.98%
301.59
Net Business Purchase And Sale
—
—
0.00
0.00
Gain Loss On Sale Of Business
-237.59
0.00
0.00
0.00
Financing Cash Flow
-42.17
-167.06%
62.88
+159.27%
-106.08
-185.38%
124.25
Cash Flow From Continuing Financing Activities
-42.17
-167.06%
62.88
+159.27%
-106.08
-185.38%
124.25
Net Issuance Payments Of Debt
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Net Long Term Debt Issuance
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Net Common Stock Issuance
39.34
+431.98%
-11.85
-154.64%
-4.65
0.00
Common Stock Payments
0.00
+100.00%
-11.85
-154.64%
-4.65
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-11.85
-154.64%
-4.65
0.00
Proceeds From Stock Option Exercised
7.65
+1298.72%
0.55
+264.67%
0.15
-63.86%
0.41
Net Other Financing Charges
—
115.53
—
125.00
Changes In Cash
6.26
+268.96%
-3.71
+5.10%
-3.90
+95.65%
-89.80
Beginning Cash Position
3.40
-52.15%
7.11
-35.46%
11.01
-89.08%
100.81
End Cash Position
9.66
+184.12%
3.40
-52.15%
7.11
-35.46%
11.01
Free Cash Flow
-116.16
+22.02%
-148.97
-300.50%
74.30
+185.80%
-86.60
Interest Paid Supplemental Data
35.42
-0.75%
35.69
+19.26%
29.92
+56.03%
19.18
Income Tax Paid Supplemental Data
0.15
-7.27%
0.17
-94.99%
3.29
+4015.00%
0.08
Amortization Of Securities
0.00
+100.00%
-4.37
+49.84%
-8.71
0.00
Common Stock Issuance
39.34
0.00
0.00
0.00
Issuance Of Capital Stock
39.34
0.00
0.00
0.00
Sale Of Business
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category